MaxCyte, Inc.

Equities

MXCT

US57777K1060

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 16:35:15 28/05/2024 BST			5-day change	1st Jan Change
362 ^GBX	-0.82%		-2.16%	+2.70%

05-22	MaxCyte inks deal with Legend Biotech for tech supply	AN
05-22	MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	MT

Maxcyte, Inc. Provides Revenue Guidance for the First Quarter of 2022

April 12, 2022 at 09:05 pm

MaxCyte, Inc. provided revenue guidance for the first quarter of 2022. For the quarter, the company expects revenue to be at least $11.0 million, compared to $6.5 million in the first quarter of 2021.

Latest news about MaxCyte, Inc.

MaxCyte inks deal with Legend Biotech for tech supply	05-22	AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	05-22	MT
MaxCyte Shares Rise Sharply After Q1 Results Beat	05-08	MT
MaxCyte shares rise amid double-digit revenue increase	05-08	AN
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M	05-08	MT
Earnings Flash (MXCT.L) MAXCYTE Reports Q1 Loss $-0.09	05-08	MT
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Earnings Flash (MXCT) MAXCYTE Reports Q1 Revenue $11.3M, vs. Street Est of $7.5M	05-07	MT
Transcript : MaxCyte, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024	05-07	CI
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	05-03	AN
MaxCyte inks deal with Be Bio; Orcadian firms farmout	04-02	AN
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	04-02	CI
BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating	03-13	MT
MaxCyte loss widens in 2023 as core revenue declines 25%	03-13	AN
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High	03-13	DJ
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Transcript : MaxCyte, Inc., 2023 Earnings Call, Mar 12, 2024	03-12
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Earnings Flash (MXCT) MAXCYTE Reports Q4 Revenue $15.7M, vs. Street Est of $15.1M	03-12	MT
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024	03-12	CI
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit	03-05	AN
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance	03-04	MT
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024	03-04	CI
MaxCyte, Wugen Enter Platform License Deal	01-30	MT

Chart MaxCyte, Inc.

Duration

Period

More charts

Company Profile

MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.

Sector

Advanced Medical Equipment & Technology

Calendar

11/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MaxCyte, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.652 USD

Average target price

6.94 USD

Spread / Average Target

+49.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
MAXCYTE, INC.	+2.70%	487M
THERMO FISHER SCIENTIFIC	+7.52%	223B
DANAHER CORPORATION	+11.52%	195B
INTUITIVE SURGICAL, INC.	+18.68%	144B
BOSTON SCIENTIFIC CORPORATION	+29.85%	111B
SIEMENS HEALTHINEERS AG	+2.32%	65.19B
EDWARDS LIFESCIENCES CORPORATION	+13.91%	53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	50.28B
AGILENT TECHNOLOGIES, INC.	+6.46%	44.15B
GE HEALTHCARE TECHNOLOGIES INC.	+1.75%	36.45B

Other Advanced Medical Equipment & Technology